학술논문
RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non small cell lung cancer (NSCLC).
Document Type
Journal
Author
Nakagawa, Kazuhiko; Garon, Edward B.; Seto, Takashi; Nishio, Makoto; Ponce Aix, Santiago; Chiu, Chao-Hua; Park, Keunchil; Novello, Silvia; Nadal, Ernest; Imamura, Fumio; Yoh, Kiyotaka; Shih, Jin-Yuan; Au, Kwok Hung; Moro-Sibilot, Denis; Enatsu, Sotaro; Zimmermann, Annamaria H.; Frimodt-Moller, Bente; Grul, Carla M. Visseren; Reck, Martin
Source
Subject
Language
English
ISSN
15277755